What is claimed:

1. A liquid composition comprising adalimumab, wherein the adalimumab is expressed in a Chinese Hamster Ovary (CHO) cell expression system; and the composition is characterized in that when the composition is assayed in a cathepsin L kinetic assay, a level of cathepsin L activity less than 1.3 RFU/s/mg of adalimumab is observed, wherein the cathepsin L kinetic assay comprises:

i) diluting the composition in a polystyrene container in a solution containing 25 mM NaOAc, 5 mM DTT and 1 mM EDTA at pH 5.5,

ii) adding dextran sulfate to a concentration of 0.035 µg/mL and incubating at 37°C for six hours,

iii) adding Z-leucine-arginine covalently bound at its C-terminus to a fluorescent 7-amino-4-methyl coumarin (Z-leucine-arginine-AMC), wherein the diluting, adding, and incubating steps are sufficient to permit the measurement of cathepsin L hydrolysis of the Z-leucine-arginine-AMC within a linear range, and

iv) measuring Z-leucine-arginine-AMC hydrolysis in the linear range in RFU/s/mg of adalimumab.

2. The liquid composition of claim 1, wherein the cathepsin L activity is no greater than 1.0 RFU/s/mg of adalimumab.

3. The liquid composition of claim 1, wherein the cathepsin L activity is no greater than 0.6 RFU/s/mg of adalimumab.

4. The liquid composition of claim 1, wherein the cathepsin L activity is no greater than 0.85 RFU/s/mg of adalimumab.

5. The liquid composition of claim 1, wherein the cathepsin L activity is no greater than 0.9 RFU/s/mg of adalimumab.

6. The liquid composition of claim 1, wherein the composition is packaged in a pre-filled syringe.

7. The liquid composition of claim 1, wherein the composition comprises 50 mg/ml of adalimumab.

8. The liquid composition of claim 1, wherein the composition is suitable for subcutaneous injection.

9. The liquid composition of claim 1, wherein the diluted composition has an adalimumab concentration of 20 µg/ml.

10. The liquid composition of claim 1, wherein the diluted composition has an adalimumab concentration of 50 µg/ml.

11. The liquid composition of claim 1, wherein step i) of the cathepsin L kinetic assay comprises diluting the composition 600 fold.

12. The liquid composition of claim 2, wherein the composition is packaged in a pre-filled syringe.

13. The liquid composition of claim 2, wherein the composition comprises 50 mg/ml of adalimumab.

14. The liquid composition of claim 2, wherein the composition is suitable for subcutaneous injection.

15. The liquid composition of claim 2, wherein the diluted composition has an adalimumab concentration of 20 µg/ml.

16. The liquid composition of claim 2, wherein the diluted composition has an adalimumab concentration of 50 µg/ml.

17. The liquid composition of claim 2, wherein step i) of the cathepsin L kinetic assay comprises diluting the composition 600 fold.

18. The liquid composition of claim 3, wherein the composition is packaged in a pre-filled syringe.

19. The liquid composition of claim 3, wherein the composition comprises 50 mg/ml of adalimumab.

20. The liquid composition of claim 3, wherein the composition is suitable for subcutaneous injection.

21. The liquid composition of claim 3, wherein the diluted composition has an adalimumab concentration of 20 µg/ml.

22. The liquid composition of claim 3, wherein the diluted composition has an adalimumab concentration of 50 µg/ml.

23. The liquid composition of claim 3, wherein step i) of the cathepsin L kinetic assay comprises diluting the composition 600 fold.